Objective: To investigate the safety of minimal immunosuppression (IS) in liver transplantation (LT). Background: The lack of long-term follow-up studies, including pathologic data, has led to a protean handling of IS in LT. Methods: Between February 2000 and September 2004, 156 adults were enrolled in a prospective, randomized, double-blind, placebo-controlled minimization trial comparing tacrolimus placebo (TAC-PLAC) and TAC shortterm steroid (TAC-STER) IS. All patients had a minimum clinical, biochemical, and histological follow-up of 5 years. Results: Five-year actual patient and graft survival rates in TAC-PLAC and TAC-STER groups were 78.1% and 82.1% (P = 0.89) and 74.2% and 76.9% (P = 0.90), respectively. Five-year biopsies were available in 112 (89.6%) of 125 survivors. Twelve patients refused a biopsy because of their excellent evolution; tissue material was insufficient in 1 patient; 11 had normal liver tests; and 2 patients had developed alcoholic and secondary biliary cirrhosis. Histology was normal in 44 (39.3%) patients; 35 (31.3%) had disease recurrence. The remaining biopsies showed nonspecific chronic hepatitis (14.3%), mild inflammatory infiltrates (10.7%), and steatosis (3.5%). All findings were equally distributed between both groups. In each group, 3 patients (4.8%) presented with acute cellular rejection after the first year and only 1 (0.9%) TAC-PLAC patient developed chronic rejection after IS withdrawal because of pneumonitis. Arterial hypertension, diabetes mellitus, renal insufficiency, hypercholesterolemia, gout, and obesity were equally low in both groups. Conclusions: Excellent long-term results can be obtained under minimal IS and absence of steroids. TAC-based monotherapy is feasible in most adult liver recipients until 5 years of follow-up. (ALT), gamma glutamyl transferase (GGT), creatinine, glycemia, uric acid, cholesterolemia and tacrolemia, body mass index (BMI), arterial hypertension, diabetes, de novo malignancy, and osteomuscular and neurologic complications were recorded yearly. Liver test values up to 2 times normal were considered normal.
S ince introduction of liver transplantation (LT) in clinical practice 50 years ago, many different, induction as well as maintenance, immunosuppression (IS) schemes have been used to achieve allograft acceptance. 1, 2 All these different approaches have been triggered by a multitude of, mostly industry-driven, studies [3] [4] [5] [6] [7] [8] and, most importantly, by the lack of well-documented long-term follow-up. [9] [10] [11] [12] This is surprising if one takes into account the many important consequences of heavy IS such as the high incidence of allograft loss due to cardiovascular, infectious, and oncologic complications 13, 14 ; the development of metabolic syndrome 15 and renal insufficiency 16, 17 ; the reduced quality of life 18 ; and the immunoprivileged status of the liver. 19, 20 All these findings should intuitively incite transplant physicians to opt for a policy of minimization IS. In the last 15 years, this approach has been applied in our transplant unit. 4, 21 This article aims at reporting the long-term outcome of such a strategy based on a welldocumented clinical, biochemical, and most importantly pathologic follow-up study in a single-center adult recipient cohort.
MATERIALS AND METHODS
Between February 2000 and September 2004, 156 consecutive, unselected, primary adults (>15 years) were included in a prospective, randomized, double-blind, placebo-controlled trial (RCT) comparing TAC-short term (64 days) STER (TAC-STER; n = 78) and TAC-Placebo (TAC-PLAC; n = 78). 21 Patient characteristics and 1-year results of this study have been reported in detail in 2008. 21 The TAC-STER group contained a higher number of HCV (hepatitis C viral infection) patients (21 vs 14 in TAC-PLAC group; ns). All patients received identical intraoperative and postoperative care. TAC levels were adjusted according to the clinical situation and progressively raised to reach trough whole blood levels around 6 to 8 ng/mL. A low TAC level was defined as below 6 ng/mL. All patients received 1000 mg hydrocortisone during the immediate perioperative period to blunt ischemia/reperfusion injury. Oral STER (methylprednisolone) and PLAC, administered in identical, opaque capsules, were tapered by steps of 4 mg to be stopped in all patients at day 64, this independently of any previously occurring immunologic event to obtain TAC monotherapy IS. During follow-up, IS was further lowered corresponding to biochemical, clinical, and histological evolution. When stable liver tests were obtained with a single infratherapeutic daily dosage of TAC, spacing therapy was started with further adaptation after 6-to 12-month intervals. This article deals with the 5-year results of this cohort. Evolution of bilirubin, alanine aminotransferas Pathologic follow-up consisted of protocol biopsies at days 7, 180, and 365 and at 5 years and when clinically indicated. HCV recipients had yearly biopsies to document progression of viral reinfection; fibrosis was scored according METAVIR. Significant fibrosis and cirrhosis were considered as F3 and F4 stages. Rejection was only treated after pathologic confirmation of clinical suspicion. Chronic rejection (ChRej) was defined as the absence of bile ducts in more than 50% of portal tracts on a representative biopsy.
The institutional review board approved this investigatordriven study, which was designed by the senior author (J.L.). Because the study started in 2000, the authors adhered to the guidelines of Consolidated Standards on Reporting Trials. Informed written consent was obtained from all patients or their next of kin before transplantation. All patients, health care providers, and outcome assessor teams were blinded until the complete 12-month analysis. All followup liver biopsies were read blindly throughout the whole study period by the liver pathologist (C.S.).
Statistical Analysis
Categorical variables were reported as number of cases and percentages. Continuous variables were provided as medians and interquartile ranges (IQR). Continuous variables were explored for parametric distribution using the Kolmogorov-Smirnov test. χ 2 and Fisher exact test were used for comparison between categorical variables. For continuous variables, student t test was done for parametric variables, and Mann-Whitney U test for nonparametric variables. A P value of less than 0.05 indicated statistical significance. Statisti-cal analyses and plots were performed with SPSS 19.0 (IBM Corp, Armonk, NY).
RESULTS

Patient and Graft Outcome
Three-and 12-month survival rates were 93.6 and 87.2% in TAC-PLAC group and 98.7 and 94.7% in the TAC-STER group (P = 0.096 and P = 0.09). 21 Five-year patient survival rates were 78.1% in the TAC-PLAC and 82.1% in the TAC-STER groups (P = 0.89). The patient flow during the 5-year study period is displayed in Table 1 . Seventeen (21%) TAC-PLAC and 14 (18%) TAC-STER patients died during the 5-year follow-up (P = 0.69). Differences between both groups in relation to the causes of death were not significant. In the TAC-STER group, more patients died because of HCV recurrence (6 vs 1 in TAC-PLAC group, P = 0.12).
Three-and 12-month graft survival rates were 92.3% and 85.9% in the TAC-PLAC group and 97.4% and 92.3% in the TAC-STER group (P = 0.14 and 0.13 respectively). 21 Five-year graft survival rates were 74.2% in the TAC-PLAC and 76.9% in TAC-STER groups (P = 0.90). Nine (5.75%) patients were retransplanted within the 5-year follow-up period. After the first post-LT year, 2 and 6 graft losses occurred in TAC-PLAC and TAC-STER groups. Two (2.5%) TAC-PLAC patients were retransplanted because of HCV recurrence and ChRej developed after IS withdrawal due to pneumonia. Six (6.4%) TAC-STER patients were retransplanted because of HCV recurrence (n = 3), intrahepatic ischemic type biliary lesions (ITBL) (n = 2), and toxic hepatitis (n = 1). 
Pathologic Follow-up
Five-year biopsy was done in 112 (89.6%) patients ( Table 2) . Twelve (9.6%) patients with stable, normal liver tests refused a biopsy (n = 11); once (0.8%) tissue material was insufficient for analysis. Biopsy results identified 44 (39.3%) patients, 22 in each group, without significant abnormalities. Twelve (10.7%), 7 TAC-PLAC and 5 TAC-STER, patients presented with findings of mild acute cellular rejection (ACR). Nonspecific chronic hepatitis was seen in 16 (14.3%) patients-7 TAC-PLAC and 9 TAC-STER patients. Severe steatosis without another histological finding was found in 4 (3.6%) patients. None of them had a change in IS because of excellent clinical and biochemical evolution. Recurrent disease was diagnosed in 35 (31.3%) patients; HCV (n = 22) and primary biliary cirrhosis (PBC) (n = 7) were the main causes of recurrence. Major fibrosis was identified in 10 HCV and 3 PBC patients. One TAC-PLAC patient developed ChRej after IS withdrawal (see earlier); she had successful re-LT; 2 TAC-STER patients developed ChRej in the context of ITBL.
IS could be lowered in 44 (38.9%) of biopsied patients; IS was reinforced in only 3 (2.6%) patients. The clinical evolution of the 13 patients for whom no 5-year biopsy was available is shown in Table 3 . The detailed analysis of the 14 TAC-PLAC and 21 TAC-STER HCV patients has been extensively reported. 22 Five-year graft (69% vs 61%; P = 0.38) and patient (69% vs 61% P = 0.46) survival rates were similar as were the composite endpoints consisting of progression to severe allograft fibrosis (F3), cirrhosis (F4), re-LT, and /or death due to allograft reinfection.
Immunologic Follow-up
Hundred (80%) of 125 patients remained on monotherapy IS during the study period (Table 4 ). Fifty-two (85.2%) TAC-PLAC and 44 (68.8%) TAC-STER patients remained on TAC monotherapy (P = 0.035). Overall TAC mean blood trough levels were progressively lowered during the study period; there were no significant differences between both groups in relation to lowering of TAC dosing throughout the study period. Five-year post-LT, median blood trough TAC levels in TAC-PLAC and TAC-STER patients on monotherapy were 3.0 (IQR: 2.0-4.0) and 3.4 (IQR: 2.4-4.2) ng/dL (P = 0.14). Patients receiving double or triple IS had slightly higher median TAC blood trough levels of 4.0 ng/dL versus 3.0 ng/dL (P = 0.01).
Two TAC-PLAC and 2 TAC-STER patients were switched to cyclosporine, mofetil mycophenolate (MMF), and sirolimus (2x) due to adverse effects of TAC. Six (9.8%) TAC-PLAC and 14 (21.8%) TAC-STER patients were on double drug IS (P = 0.09); 1 (1.6%) TAC-PLAC and 4 (6.3%) TAC-STER were on triple drug IS (P = 0.37). This adaptation of IS was necessary in the TAC-PLAC group because of recurrent PBC (3x) and impaired renal function (3x); 1 patient received sirolimus because of recurrent neuroendocrine disease. In the TAC-STER group, IS had to be modified because of impaired renal function (9x), neurotoxicity (3x), recurrent PBC (2x), autoimmune hepatitis (1x), status postcorticoresistant rejection treatment (2x), and mesenteric recurrence of neuroendocrine tumor (1x). One patient in each patient cohort had a kidney transplantation.
Significantly more TAC-PLAC patients were on TACmonotherapy (52/61 pats vs 44/64 pats; P = 0.035) and on monotherapy (54/61 pats vs 46/64 TAC-STER pats; P = 0.025). Thirteen (10.4%) patients are on spaced IS therapy: 3 (4.9%) TAC-PLAC and 10 (15.6%) TAC-STER patients (P = 0.08). No patient in both study groups was off IS. Six (4.8%) patients, 3 in each group, presented with ACR after the first year. Five were successfully treated with five 200-mg oral steroid boluses; 1 patient needed polyclonal antibodies. ACR treatment did not impact on HCV recurrence. 22 Three (2.4%) patients developed chronic rejection; 2 in TAC-PLAC and 1 in TAC-STER group (P = 1.00).
Clinical and Metabolic Follow-up
Evolution of liver and renal tests, glycemia, incidence of (de novo) diabetes mellitus and arterial hypertension, renal insufficiency, dyslipidemia, gout, obesity (BMI > 28), and Karnofsky performance index were similarly low in both groups. Creatinine clearance values were well preserved ( Table 5 ).
DISCUSSION
Since the introduction of LT 50 years ago, surgical technique and medical care have been, in contrast to induction as well as maintenance, immunosuppressive treatment, progressively standardized. 1, 23 Indeed, today's IS regimen include various combinations at different doses of calcineurin inhibitors (CNI), antimetabolites, mTor inhibitors, steroids, and different antibody-based therapies. This diverse approach has been largely triggered by a multitude of multicentric studies, set up by the pharmaceutical industry, to minimize CNI and/or steroid toxicity. [3] [4] [5] [6] [7] [8] The frequent insufficient sample size, heterogeneous trial design, lack of relevant RCTs, and most of all absence of well documented, long-term follow-up do not allow firm conclusions to be made in relation to which IS strategy to follow. Despite this, several messages can be taken to the clinical arena: (a) the superiority of CNIs as the mainstay of IS 3 ; (b) and of TAC in terms of overall and rejection-free survival rates 24 ; (c) inadequacy of CNI-free induction IS due to high ACR rates 23 ; (d) misleading of conclusions in most studies focusing on the superiority of several drug combinations in relation to steroid and CNI sparing as CNI dosing in the control arms is usually higher than advocated in the sparse, well-designed minimization RCTs 23, [25] [26] [27] ; (e) the necessity for individualized IS in HCV-infected and cancer patients [28] [29] [30] ; (f) interference of heavy IS with the active process of tolerance induction 21, 22, 31 ; and last but not least (g) the inability to make firm conclusions about the "optimal" lS regimen in absence of well-documented long-term pathologic follow-up. It is indeed well known that normal liver function tests do not necessarily correlate with normal biopsy and viceversa. [9] [10] [11] 32, 33 These observations are also valid for other transplanted organs. 34, 35 The relationship between CNI or steroids and posttransplant renal insufficiency (in 20%), 16 metabolic syndrome (in 40%) with its components diabetes, hypertension, dyslipidemia, obesity, and cardiovascular disease has been clearly identified. 13, 14 The same holds for the relationship between heavy (multidrug) IS, recurrent hepatocellular and de novo cancer, and impaired quality of life. 14, 18 Steroids are without doubt the most injurious drug in relation to physical and psychic morbidity and health-related quality of life. 4, 18, 36 Padbury's landmark article about successful LT under STER withdrawal 37 fostered interest in clinical trials addressing minimization or freedom from steroids. 21, [38] [39] [40] Similar approaches were developed in kidney, pancreas, and heart transplantation. 34, 41 A recent meta-analysis showed that steroid-(almost) free status can be obtained after LT without jeopardizing graft and patient survival rates even in the absence of induction IS and moreover results in a clear metabolic benefit. 4 These findings indicate that any minimization IS regimen should be void of this drug. 4, 5, 21, 26, 27 Unfortunately, almost all steroid sparing trials are based on a triple or even quadruple IS regimen, thereby eliminating the advantage of the minimization concept. 4, 21, 39, 40 The same holds true for most CNI sparing trials, which aim to counteract early and late post-LT nephrotoxicity. Although reduction of CNI by 30% to 50% in association with MMF as well as replacement of CNI with proliferation signal inhibitors have both been shown to be safe, 6, 7, 42, 43 most trials include steroids as part of the induction IS. The problem of all these trials relates to the fact that firm conclusions cannot be made because long-term clinical, biochemical, and, especially, pathologic data are lacking. 11, 12 The Mainz and Barcelona groups set up an early steroid-free TAC-based double-blind RCTs with steroid tapering from day 14 over a 3-to 6-month period. 26, 27 Both studies showed that such a strategy is safe. The Barcelona study, which involved HCV patients only, did not demonstrate a beneficial effect of early steroid withdrawal on post-LT HCV evolution. It should be noted that in the Mainz study, one third of patients did not complete the trial, that graft loss due to chronic rejection reached a significant 10% in the TAC-PLAC group and that the 5-year follow-up report did not include biopsies. 44 Our study has the virtue of including long-term follow-up. To the best of our knowledge, we report for the first time in LT literature, the 5-year results, including the pathologic analysis, of a prospective double-blind, placebo-controlled, almost steroid avoiding TAC-based IS minimization RCT. STER administration was limited to the perioperative period only to counteract ischemia reperfusion injury. 45 Short-and long-term patient and graft survival rates were similar in the TAC-PLAC and short-term TAC-STER cohorts. The same was true for infectious, tumor-related, and metabolic complications. Moreover long-term pathologic follow-up data, obtained in 90% of survivors, confirms that such strategy is safe as shown by the very low incidences of delayed (>1 year) acute and chronic rejection. The observation that "nonmonotherapy" long-term maintenance IS was significantly more frequent in the TAC-STER cohort might go along with the tolerance breaking effect of early steroid administration. 46 Such differences were not found in relation to spaced monotherapy. Spaced therapy per se should not necessarily be interpreted in the context of the "tolerance concept" as indeed many patients refused to change from a daily to an intermittent intake of their IS because of fear for rejection and more frequent medical controls and blood testing. Incidence of HCV allograft reinfection and composite endpoints consisting of progression to severe fibrosis or cirrhosis, re-LT, and death due to allograft reinfection were similar for both IS regimens. 22 These findings indicate that the evolution of HCV reinfection is mainly determined by the IS itself rather than by different induction and maintenance IS regimen. 28, 29 A recent study indicates that HCV recipients may benefit from an IS regimen that includes low-dose steroids and azathioprine. 29 Our study underlines the importance of routine liver biopsies as part of long-term follow-up of liver recipients. 11, 12, 32, 33, 47 Integration of clinical, biochemical, and pathologic information is necessary to fine-tune long-term IS treatment. Such an approach may be valuable to reduce the number of liver recipients going toward renal replacement therapy; to reduce the loss of functioning grafts due to lethal cardiovascular, infectious, and oncologic events; and to facilitate IS withdrawal in tolerance induction protocols. Moreover, plasma cell hepatitis, de novo "auto-immune" hepatitis, and fibrosis, all possibly related to immune allograft "dysfunction," are more frequently diagnosed. 10, 33 Their real meaning can only been determined by pathologic monitoring. These elements point toward the necessity to set up "biopsy clinics" to progress in induction, maintenance, and tolerance induction projects. The results obtained in minimization IS trials should stimulate the transplant community to move from the "passive" industry driven to the more "active" investigator-driven studies. 43, [48] [49] [50] Such change in attitude will be the only way to progress further in the field of both IS and operational tolerance induction. 50
CONCLUSIONS
LT can be performed safely in adult recipients without use of steroids and with minimal IS. TAC monotherapy is a feasible option in the majority of adult liver recipients. Clinical applicable guidelines in relation to the "optimal" IS can only be made if long-term follow-up, including pathology, is available.
DISCUSSANTS
A. Pinna (Bologna, Italy):
New immunosuppressive drugs and the improvement in surgical technique have made solid organ transplantation an effective treatment for end-stage organ failure. However, long-term IS can cause irreversible organ or system damages, and eventually, death. We know from the early works of Calne and Starzl that recipients of solid organs can achieve spontaneous tolerance, provided that we do not break this process with unnecessary overimmunosuppression. This paper by Lerut and his coworkers focuses on spontaneous tolerance after LT using the strategy of lowered IS. Short-and longterm patients and graft survival were similar in both groups. However, patients and graft survival at 12 months were lower in the TAC-only group than in the TAC-STER group, though not statistically different.
Furthermore, 85% of the patients on only TAC were able to be kept on monotherapy, compared to only 69% of the patients in the TAC-STER group. Only 13 patients underwent a spacing IS regimen, despite the fact that at least 44 of them had a normal liver function test and graft pathology. Finally, the study was able to demonstrate the immunological efficacy of minimal tacrolimus IS monotherapy in the long-term. However, A.A. showed that 8% of the surviving patients still had renal insufficiency, 34% had diabetes, 30.4% had a BMI greater than 28, 26.5% presented arterial hypertension with medications, and 15% had hypercholesterolemia after 5 years.
Questions:
1. Fourteen percent of the patients showed nonspecific hepatitis, whereas 5 presented ischemic diffuse biliary damage. Is this chronic rejection or donor-specific antibodies persistence immune damage? 2. Why did only 13 patients undergo spacing IS, while at least 65 of the patients had normal liver function tests and/or normal liver graft pathology? 3. How do you explain that 27% of the surviving patients on TAC-STER were shifted to triple IS? 4. Considering the incidence of cardiovascular and metabolic alterations in your patients, do you think we should probably switch to mTor inhibitor monotherapy earlier or induce IS with monoclonal antibodies, followed by earlier spacing IS?
Thank you, Ian, for having allowed me to review your paper. I present you my most sincere compliments for the study you have conducted.
Response From J. Lerut (Brussels, Belgium):
Thank you for your interesting questions. I did not point out the 1-year results in detail because they have been published before. Briefly, both groups were similar. For hepatitis C patients, I didn't go into detail either. I will try to answer your different questions. In HCV patients, it is better to have a common endpoint. In this study, we considered the endpoint to be patients dying of a recurrent HCV infection, those retransplanted because of an HCV allograft reinfection, and those dying of HCV cirrhosis. Taking into account this composite endpoint, there were absolutely no differences between the 2 groups. We also looked at the HCV-RNA levels in about half of the patients; there was again no difference in relation to the immunosuppressive scheme. So, for me, this signifies that it is not the type of IS you use, but the IS itself, per se, that kills your patient and graft.
In relation to the spacing, the problem is that over time, from the day of transplantation to 60 months, we continuously lowered the level of tacrolimus. Several patients, as you have seen, who have an unmeasurable level in their blood, continue to take low doses of tacrolimus (ie, 0.5 mg). Many of them refused to take part in a spacing project because it is too consequential. It is a huge psychological problem for a patient who has been well for 5 years. If you have a patient who you intend to follow-up, for instance, after 3 or 4 years, you need to plan a patient visits and blood tests every 3 months. Once you start spacing, you have to increase the frequency of the blood tests to one every 1 to 2 weeks. As such, the patient becomes medicalized once again and this is the main reason why many patients refuse to follow spacing therapy.
In relation to the switch, you have seen that the loss of renal function is not a big problem with our approach. Of course, mTor inhibition has been shown, in many studies, to be beneficial in sparing renal function, but we also know from clinical practice that you have to stop this medication in up to 50% of the patients. Several patients even end up asking to return to tacrolimus because they feel better when they take it.
To return to your question about steroids, and more specifically, the tolerance-breaking effect, I am a great believer in the notion that tolerance can be broken by steroids, and this has been well proven in many experimental settings and also by our group many years ago. We should also remember that a patient who is on steroids has a steroid-adapted immune system, rendering it more difficult to remove the IS within them.
In relation to the nonspecific hepatitis observed in these patients, this is, of course, a problem. In all studies about tolerance and reduction of IS, the most important is the fact that there is a lack of long-term biopsies. This is true for heart, liver, and kidney transplantations. In kidney transplantations, only 3 or 4 studies with a systematic 5-year biopsy are available. In LT, I am not aware of any study with a systematic biopsy after 5 to 10 years. Some publications speak about the result of biopsies after 5 or 10 years, but these are usually reports done in some patients as a part of a greater patient cohort. We do not yet know what is the meaning of nonspecific hepatitis. It might be an immunological dysfunction.
To return to the destruction of the bile ducts, this is also a difficult problem. Whether this microscopic destruction of the bile ducts is related to the expression of underimmunosuppression, I am unsure. Although this matter has been addressed by Jake Demetris from Pittsburgh in an excellent recent review, I personally think that further long-term biopsies must be done to give answers and draw sound conclusions.
DISCUSSANTS E. Barroso (Lisbon, Portugal):
Thank you, Dr Lerut. I just have one short question. I understand your fundamentalism against the corticosteroids because we do not like them at all. But, I do not understand your fundamentalism when it comes to favoring tacrolimus in monotherapy. As you taught us, now we have the time for an IS "à la carte," depending on the diagnosis. You have patients who can't stop taking corticosteroids due to some autoimmune diseases such as primary biliary cirrhosis and in whom cyclosporine could also be better. So, could you explain why you insist in performing monotherapy with tacrolimus?
Response From J. Lerut (Brussels, Belgium):
First of all, my message is not to stop steroids; it is, in fact, to not use them at all. It has been proven, for instance, in a recent Chinese study, that the recurrence of cancer in patients who have been immunosuppressed without steroids is reduced by 20%; of course, this is overruled by the microvascular invasion of the tumor.
Indeed, we have not used steroids anymore in our center for the past 20 years. One should keep in mind that any IS, even the most minimal one, is even too much. I agree with you that we must work "à la carte"; yet, this is not so simple. For instance, it has been claimed that patients with primary biliary cirrhosis feel better with cyclosporine than with tacrolimus. However, this has, in fact, not been unequivocally proven. The issue is that all these results are generated from industry-driven studies, and as you may know, we reacted several times against many of these industry-driven immunosuppressive drug trials. We firmly believe that there is no need for all these drugs to improve kidney function.
I think we should work to find which is the best drug before lowering its dose. If you let nature run its course, lowering your dose, and observe that no rejection occurs, then you will be able to lower the dose again after 3 and 6 months. In our patient cohort, there are surely about 40 patients in whom we do not measure tacrolimus in the blood anymore, as there is no need; yet the patient still takes daily medication. We can only progress in this field of transplantation by setting up biopsy clinics and by doing many more transplantations.
